New oral gel could tame tough tumors with fewer side effects

NCT ID NCT06143774

Recruiting now Disease control Sponsor: TaiRx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an oral gel called TRX-920 in 30 people with advanced solid tumors that no longer respond to standard treatments. The gel contains SN38, a powerful anti-cancer drug, and aims to shrink tumors with fewer side effects than the current IV version. The main goals are to find the safest dose and check how well the body tolerates it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

China Medical University Hospital
RECRUITING

Taichung, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
National Cheng-Kung University Hospital
RECRUITING

Tainan, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Taipei Medical University Hospital
RECRUITING

Taipei, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••